ENDO 2026 in Chicago will include a session titled “Year in Bone” featuring two leading experts in bone research who will review and discuss the most influential and cutting‑edge publications from the past year. Endocrine News provides a sneak peek of the talks on this “mysterious and dynamic tissue.” Last February, a paper appeared in the Journal of Bone and Mineral Research titled, “Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women.” The authors of the paper by Namki Hong, et al., write that the drug romosozumab following anti-resorptive can be an effective sequential treatment strategy to improve bone strength. However, whether the transition to romosozumab after denosumab is associated with greater improvement in bone mineral density (BMD) and trabecular bone score (TBS) compared with denosumab continuation remains unclear, the authors continue.
Endocrine News published a clinical update in Research Highlights on 27 May 2026.
The item focuses on Boning Up: The Year in Bone ENDO 2026 Preview.
Review the original article for the full source wording and details.